BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 25975284)

  • 1. Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2).
    Hechtman JF; Liu W; Sadowska J; Zhen L; Borsu L; Arcila ME; Won HH; Shah RH; Berger MF; Vakiani E; Shia J; Klimstra DS
    Mod Pathol; 2015 Aug; 28(8):1123-9. PubMed ID: 25975284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and spectrum of pathogenic germline variants in intestinal and pancreatobiliary type of ampullary cancer.
    Kumari N; Singh RK; Mishra SK; L R; Mohindra S; Krishnani N
    Pathol Res Pract; 2021 Jan; 217():153309. PubMed ID: 33341547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational profiling and immunohistochemical analysis of a surgical series of ampullary carcinomas.
    Harthimmer MR; Stolborg U; Pfeiffer P; Mortensen MB; Fristrup C; Detlefsen S
    J Clin Pathol; 2019 Nov; 72(11):762-770. PubMed ID: 31256008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular analysis of PIK3CA, BRAF, and RAS oncogenes in periampullary and ampullary adenomas and carcinomas.
    Schönleben F; Qiu W; Allendorf JD; Chabot JA; Remotti HE; Su GH
    J Gastrointest Surg; 2009 Aug; 13(8):1510-6. PubMed ID: 19440799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combined application of immunohistochemical markers to identify pathologic subtypes of ampullary carcinoma and its clinical significance].
    Liu FF; Shen DH; Wang HL; Ma YT; Yuan F; Liu J; Chen L; Song QJ; Zhang YY
    Zhonghua Bing Li Xue Za Zhi; 2019 Feb; 48(2):92-97. PubMed ID: 30695858
    [No Abstract]   [Full Text] [Related]  

  • 6. Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value.
    Kwon MJ; Kim JW; Jung JP; Cho JW; Nam ES; Cho SJ; Kim JS; Park HR; Min SK; Seo J; Min KW; Kim DH; Jeon JY
    Hum Pathol; 2016 Apr; 50():90-100. PubMed ID: 26997442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 and p21/Waf1 protein expression and K-ras codon 12 mutation in carcinoma of the papilla of Vater.
    Zhao B; Kimura W; Futakawa N; Muto T; Kubota K; Harihara Y; Takayama T; Makuuchi M
    Am J Gastroenterol; 1999 Aug; 94(8):2128-34. PubMed ID: 10445539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent MET copy number gain and KRAS mutation is a poor prognostic factor in pancreatobiliary subtype ampullary cancers.
    Kwon MJ; Kim JW; Jeon JY; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Min KW; Choe JY; Lee HK
    Pathol Res Pract; 2017 Apr; 213(4):381-388. PubMed ID: 28214200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-215 overexpression distinguishes ampullary carcinomas from pancreatic carcinomas.
    Choi DH; Park SJ; Kim HK
    Hepatobiliary Pancreat Dis Int; 2015 Jun; 14(3):325-9. PubMed ID: 26063036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor signaling pathway is frequently altered in ampullary carcinoma at protein and genetic levels.
    Mikhitarian K; Pollen M; Zhao Z; Shyr Y; Merchant NB; Parikh A; Revetta F; Washington MK; Vnencak-Jones C; Shi C
    Mod Pathol; 2014 May; 27(5):665-74. PubMed ID: 24186143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An immunohistochemical study of p53 protein in gallbladder and extrahepatic bile duct/ampullary carcinomas.
    Teh M; Wee A; Raju GC
    Cancer; 1994 Sep; 74(5):1542-5. PubMed ID: 7520348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogies.
    Castiglione R; Alidousty C; Holz B; Wagener S; Baar T; Heydt C; Binot E; Zupp S; Kron A; Wolf J; Merkelbach-Bruse S; Reinhardt HC; Buettner R; Schultheis AM
    Mod Pathol; 2019 May; 32(5):627-638. PubMed ID: 30459450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histopathologic features and microsatellite instability of cancers of the papilla of vater and their precursor lesions.
    Ruemmele P; Dietmaier W; Terracciano L; Tornillo L; Bataille F; Kaiser A; Wuensch PH; Heinmoeller E; Homayounfar K; Luettges J; Kloeppel G; Sessa F; Edmonston TB; Schneider-Stock R; Klinkhammer-Schalke M; Pauer A; Schick S; Hofstaedter F; Baumhoer D; Hartmann A
    Am J Surg Pathol; 2009 May; 33(5):691-704. PubMed ID: 19252434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene amplification of CCNE1, CCND1, and CDK6 in gastric cancers detected by multiplex ligation-dependent probe amplification and fluorescence in situ hybridization.
    Ooi A; Oyama T; Nakamura R; Tajiri R; Ikeda H; Fushida S; Dobashi Y
    Hum Pathol; 2017 Mar; 61():58-67. PubMed ID: 27864121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas.
    Dias-Santagata D; Lam Q; Bergethon K; Baker GM; Iafrate AJ; Rakheja D; Hoang MP
    Mod Pathol; 2011 Jul; 24(7):974-82. PubMed ID: 21423156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunophenotyping and oncogene amplifications in tumors of the papilla of Vater.
    Baumhoer D; Zlobec I; Tornillo L; Dietmaier W; Wuensch PH; Hartmann A; Sessa F; Ruemmele P; Terracciano LM
    Virchows Arch; 2008 Dec; 453(6):579-88. PubMed ID: 18936968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The utility of immunohistochemistry in subtyping adenocarcinoma of the ampulla of vater.
    Ang DC; Shia J; Tang LH; Katabi N; Klimstra DS
    Am J Surg Pathol; 2014 Oct; 38(10):1371-9. PubMed ID: 24832159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiation and prognostic markers in ampullary cancer: Role of p53, MDM2, CDX2, mucins and cytokeratins.
    Perysinakis I; Minaidou E; Mantas D; Sotiropoulos GC; Leontara V; Tsipras H; Zografos GN; Margaris I; Kouraklis G
    Pathol Res Pract; 2016 Nov; 212(11):1039-1047. PubMed ID: 27688085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations.
    Mafficini A; Amato E; Cataldo I; Rusev BC; Bertoncello L; Corbo V; Simbolo M; Luchini C; Fassan M; Cantù C; Salvia R; Marchegiani G; Tortora G; Lawlor RT; Bassi C; Scarpa A
    Ann Surg; 2018 Jan; 267(1):149-156. PubMed ID: 27611608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.
    Ross JS; Fakih M; Ali SM; Elvin JA; Schrock AB; Suh J; Vergilio JA; Ramkissoon S; Severson E; Daniel S; Fabrizio D; Frampton G; Sun J; Miller VA; Stephens PJ; Gay LM
    Cancer; 2018 Apr; 124(7):1358-1373. PubMed ID: 29338072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.